Yes. And those "ramblings" are common, as can also be found here. Everyone thinks their MOA is the key, and that their drug is the special snowflake. ('Management thinks it is, so it must be.')
But clinical trials are very good at revealing what is actually clinical therapeutic, and are what regulators and investors watch. Everyone should, but it takes some patience.
Market Data 
Markets 
AI
